Enginzyme AB has closed a new equity round totaling SEK 75 million, a move that marks a major milestone in the company's commercial development. The Sweden-based business announced the funding as part of its wider shift from research and development to a commercially driven strategy. The fresh capital will help the company deliver enzyme-based biomanufacturing solutions to the personal care, food, and pharmaceutical industries.
Strategic Purpose of the Investment
The capital injection is designed to accelerate Enginzyme's commercial roadmap and scale its proprietary technology for industrial partners. Enginzyme said the round reflects growing confidence in its ability to lower production costs while improving ingredient quality and sustainability. The financing is viewed as foundational for expanding the company's market presence and technical deployment across target sectors.
Chief Executive Officer Aymeric de Gantes emphasized that closing the round was a priority after the company established its growth strategy. He noted that the new shareholders bring complementary expertise that will support the company's commercial mission. He also explained that the technology enables lower cost in use for higher quality ingredients obtained through more sustainable manufacturing processes.
The investment marks a clear step away from a pure research focus toward an operational model built around commercial delivery. Enginzyme said its growth strategy now prioritizes serving global manufacturers with scalable biomanufacturing processes and repeatable industrial outcomes. This shift is expected to help the company convert its technical capabilities into broader adoption across its target markets.
Investor Participation and Governance
The funding round welcomes Lotus One Investment Pte. Ltd. and Valquest Partners Europe as new shareholders and members of the Board of Directors. Existing investors including Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB, and Almi Invest GreenTech played key roles in the round. A broader group of new and existing shareholders also participated, strengthening the company's investor base.
Enginzyme hosted a stakeholder gathering at its offices and laboratories on the Karolinska tech campus in Solna on Thursday, September 17. The event brought together investors, partners, and team members to mark the closing of the financing and to discuss future commercial plans. It underscored the company's collaborative approach as it moves toward larger scale commercial engagements and deeper industry partnerships.
Biomanufacturing Technology and Applications
Enginzyme specializes in enzyme immobilisation technology that allows biomanufacturing without the use of living organisms. This patented approach can be applied to create more cost efficient and sustainable production processes compared to traditional chemical manufacturing. The company focuses on ingredients for personal care, food, and pharmaceutical applications, serving global manufacturers from early analysis to industrial production.
The company's multidisciplinary team includes experts in enzyme and process engineering, biocatalysis, and organic chemistry. Its technology is intended to reduce environmental footprint while maintaining high quality output standards for manufacturers in demanding industries. Enginzyme supports clients through techno-economic analysis, process development, and industrial manufacture, aiming to deliver lower overall costs at scale and improve production sustainability.
The SEK 75 million equity round positions Enginzyme to advance its commercial strategy and deepen partnerships with global manufacturers. New investor expertise and board representation are expected to support the company's next phase of growth and market expansion. With its enzyme based platform, Enginzyme aims to make industrial biomanufacturing more accessible, sustainable, and cost effective across personal care, food, and pharmaceutical industries.